U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C45H50ClN7O7S
Molecular Weight 868.4419
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VENETOCLAX

SMILES

CC1(C)CCC(=C(C1)c2ccc(cc2)Cl)CN3CCN(CC3)c4ccc(c(c4)Oc5cc-6ccnc6[nH]c5)C(=NS(=O)(=O)c7ccc(c(c7)N(=O)=O)NCC8CCOCC8)O

InChI

InChIKey=LQBVNQSMGBZMKD-UHFFFAOYSA-N
InChI=1S/C45H50ClN7O7S/c1-45(2)15-11-33(39(26-45)31-3-5-34(46)6-4-31)29-51-17-19-52(20-18-51)35-7-9-38(42(24-35)60-36-23-32-12-16-47-43(32)49-28-36)44(54)50-61(57,58)37-8-10-40(41(25-37)53(55)56)48-27-30-13-21-59-22-14-30/h3-10,12,16,23-25,28,30,48H,11,13-15,17-22,26-27,29H2,1-2H3,(H,47,49)(H,50,54)

HIDE SMILES / InChI
Venetoclax (trade name Venclexta, also known as ABT-199) is a selective and orally bioavailable small-molecule inhibitor of BCL-2, an antiapoptotic protein. BCL-2 and its related proteins BCL-XL and MCL-1 bind to and sequester pro-apoptotic signals in the cell, causing a down-regulation of apoptosis. As an oncogene and an important regulator of apoptosis, BCL-2 overexpression therefore results in increased tumor cell survival and resistance to chemotherapy. FDA approved Venetoclax in April 2016 for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. Also this drug in phase 3 clinical trial in combination therapy for the treatment patients with refractory myeloma and Acute Myeloid Leukemia. Common side effects include neutropenia, nausea, anemia, diarrhea, upper respiratory tract infection. Major side effects include tumor lysis syndrome and severe neutropenia.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VENCLEXTA

Approved Use

VENCLEXTA is a BCL-2 inhibitor indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) with 17p deletion, as detected by an FDA approved test, who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Launch Date

1.46033279E12
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2.1 μg/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: LOW-FAT
1.43 μg/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
32.8 μg × h/mL
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: LOW-FAT
30.2 μg × h/mL
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
14.1 h
400 mg 1 times / day multiple, oral
dose: 400 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: HIGH-FAT
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
400 mg 1 times / day steady-state, oral
dose: 400 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VENETOCLAX plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: UNKNOWN
food status: LOW-FAT
Doses

Doses

DosePopulationAdverse events​
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Disc. AE: Nausea, Diarrhea...
Other AEs: Nausea, Diarrhea...
AEs leading to
discontinuation/dose reduction:
Nausea (5 patients)
Diarrhea (4 patients)
Other AEs:
Nausea (grade 1-2, 53%)
Diarrhea (grade 1-2, 53%)
Diarrhea (grade 3-4, 2%)
Fatigue (grade 1-2, 49%)
Fatigue (grade 3-4, 6%)
Decreased appetite (grade 1-2, 29%)
Vomiting (grade 1-2, 24%)
Constipation (grade 1-2, 18%)
Headache (grade 1-2, 20%)
Anemia (grade 1-2, 10%)
Anemia (grade 3-4, 8%)
Cough (grade 1-2, 10%)
Neutropenia (grade 1-2, 12%)
Neutropenia (grade 3-4, 8%)
Back pain (grade 1-2, 16%)
Back pain (grade 3-4, 2%)
Upper respiratory tract infection (grade 1-2, 8%)
Sources:
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Disc. AE: Neutropenia, Thrombocytopenia...
Other AEs: Neutropenia, Neutrophil count decreased...
AEs leading to
discontinuation/dose reduction:
Neutropenia (grade 3-4, 41%)
Thrombocytopenia (grade 3-4, 15%)
Febrile neutropenia (serious, 2%)
Anemia hemolytic autoimmune (serious, 2%)
Other AEs:
Neutropenia (all grades, > 20)
Neutrophil count decreased (all grades, 45%)
Neutrophil count decreased (grade 3-4, 41%)
Diarrhea (all grades, > 20)
Diarrhea (grade 3-4, <1%)
Nausea (grade 3-4, <1%)
Nausea (all grades, > 20)
Anemia (all grades, > 20)
Anemia (grade 3-4, 18%)
Hemoglobin decreased (all grades, 29%)
Hemoglobin decreased (grade 3-4, 18%)
Upper respiratory tract infection (all grades, > 20)
Thrombocytopenia (all grades, > 20)
Platelet count decreased (all grades, 22%)
Platelet count decreased (grade 3-4, 15%)
Fatigue (all grades, > 20)
Fatigue (grade 3-4, 2%)
Pneumonia (serious, 2%)
Pyrexia (serious, 2%)
Anemia (serious, 2%)
Tumor lysis syndrome (serious, 2%)
Vomiting (all grades, 15%)
Vomiting (grade 3-4, <1%)
Constipation (all grades, 14%)
Peripheral edema (all grades, 11%)
Peripheral edema (grade 3-4, <1%)
Upper respiratory tract infection (all grades, 22%)
Upper respiratory tract infection (grade 3-4, 1%)
Pneumonia (all grades, 8%)
Pneumonia (grade 3-4, 5%)
Hypokalemia (all grades, 12%)
Hypokalemia (grade 3-4, 4%)
Back pain (all grades, 10%)
Back pain (grade 3-4, <1%)
Headache (all grades, 15%)
Headache (grade 3-4, <1%)
Cough (all grades, 13%)
Sources:
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: relapsed/refractory MM
Population Size: 9
Sources:
DLT: Nausea, Abdominal pain...
Dose limiting toxicities:
Nausea (grade 3, 1 patient)
Abdominal pain (grade 2, 1 patient)
Vomiting (grade 3, 1 patient)
Epigastralgia (grade 3, 1 patient)
Sources:
AEs

AEs

AESignificanceDosePopulation
Diarrhea 4 patients
Disc. AE
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Nausea 5 patients
Disc. AE
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Anemia grade 1-2, 10%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Cough grade 1-2, 10%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Neutropenia grade 1-2, 12%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Back pain grade 1-2, 16%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Constipation grade 1-2, 18%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Headache grade 1-2, 20%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Vomiting grade 1-2, 24%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Decreased appetite grade 1-2, 29%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Fatigue grade 1-2, 49%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Diarrhea grade 1-2, 53%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Nausea grade 1-2, 53%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Upper respiratory tract infection grade 1-2, 8%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Back pain grade 3-4, 2%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Diarrhea grade 3-4, 2%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Fatigue grade 3-4, 6%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Anemia grade 3-4, 8%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Neutropenia grade 3-4, 8%
1200 mg 1 times / day steady, oral
Highest studied dose
Dose: 1200 mg, 1 times / day
Route: oral
Route: steady
Dose: 1200 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 25 - 86 years)
n = 52
Health Status: unhealthy
Condition: Relapsed or Refractory Non-Hodgkin Lymphoma
Age Group: 66 years (range: 25 - 86 years)
Sex: M+F
Population Size: 52
Sources:
Back pain all grades, 10%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Peripheral edema all grades, 11%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Hypokalemia all grades, 12%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Cough all grades, 13%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Constipation all grades, 14%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Headache all grades, 15%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Vomiting all grades, 15%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Platelet count decreased all grades, 22%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Upper respiratory tract infection all grades, 22%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Hemoglobin decreased all grades, 29%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Neutrophil count decreased all grades, 45%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Pneumonia all grades, 8%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Anemia all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Diarrhea all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Fatigue all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Nausea all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Neutropenia all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Thrombocytopenia all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Upper respiratory tract infection all grades, > 20
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Upper respiratory tract infection grade 3-4, 1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Platelet count decreased grade 3-4, 15%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Thrombocytopenia grade 3-4, 15%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Anemia grade 3-4, 18%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Hemoglobin decreased grade 3-4, 18%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Fatigue grade 3-4, 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Hypokalemia grade 3-4, 4%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Neutrophil count decreased grade 3-4, 41%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Neutropenia grade 3-4, 41%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Pneumonia grade 3-4, 5%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Back pain grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Diarrhea grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Headache grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Nausea grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Peripheral edema grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Vomiting grade 3-4, <1%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Anemia serious, 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Pneumonia serious, 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Pyrexia serious, 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Tumor lysis syndrome serious, 2%
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Anemia hemolytic autoimmune serious, 2%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Febrile neutropenia serious, 2%
Disc. AE
400 mg 1 times / day steady, oral
Recommended
Dose: 400 mg, 1 times / day
Route: oral
Route: steady
Dose: 400 mg, 1 times / day
Sources:
unhealthy, 66 years (range: 29 - 85 years)
n = 240
Health Status: unhealthy
Condition: CLL
Age Group: 66 years (range: 29 - 85 years)
Sex: M+F
Population Size: 240
Sources:
Abdominal pain grade 2, 1 patient
DLT
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: relapsed/refractory MM
Population Size: 9
Sources:
Epigastralgia grade 3, 1 patient
DLT
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: relapsed/refractory MM
Population Size: 9
Sources:
Nausea grade 3, 1 patient
DLT
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: relapsed/refractory MM
Population Size: 9
Sources:
Vomiting grade 3, 1 patient
DLT
600 mg 1 times / day steady, oral
Dose: 600 mg, 1 times / day
Route: oral
Route: steady
Dose: 600 mg, 1 times / day
Sources:
unhealthy
n = 9
Health Status: unhealthy
Condition: relapsed/refractory MM
Population Size: 9
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
yes [IC50 0.13 uM]
yes [IC50 0.14 uM]
yes [IC50 0.79 uM]
yes [IC50 0.82 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: Co-administration of ketoconazole (a strong CYP3A, P-gp and BCRP inhibitor) increased venetoclax Cmax and AUCX by 2.3- and 6.4-fold, respectively. Co-administration of moderate CYP3A4/5 inhibitors showed a smaller effect on venetoclax exposrue (40 to 60% increase in Cmax and AUCo-24)-
Page: 6.0
no
no
yes
yes
yes (co-administration study)
Comment: Venetoclax exposure also increased (Cmax t 106%, AUCX T 78%) after co-administration of single dose of rifampin, presumably due to the inhibition of P-gp by rifampin.
Page: 6.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Novel therapies for chronic lymphocytic leukemia.
2004 Jun
An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
2005 Jun 2
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options.
2015 Sep
Patents

Sample Use Guides

Initiate therapy with VENCLEXTA (venetoclax) at 20 mg once daily for 7 days, followed by a weekly ramp-up dosing schedule to the recommended daily dose of 400 mg. VENCLEXTA tablets should be taken orally once daily with a meal and water.
Route of Administration: Oral
ABT-199 (Venetoclax) shows less sensitivity to Bcl-xL, Mcl-1 and Bcl-w with Ki of 48 nM, > 444 nM and 245 nM, respectively. ABT-199 potently inhibits FL5.12-Bcl-2 cells, RS4;11 cells with EC50 of 4 nM and 8 nM, while shows low activity against FL5. ABT-199 also induces apoptosis in CLL with an average EC50 of 3.0 nM.
Name Type Language
VENETOCLAX
DASH   INN   USAN   WHO-DD  
USAN   INN  
Official Name English
RG7601
Code English
ABT-199
Code English
VENETOCLAX [INN]
Common Name English
VENCLEXTA
Brand Name English
VENETOCLAX [ORANGE BOOK]
Common Name English
VENETOCLAX [USAN]
Common Name English
4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2HPYRAN-4-YLMETHYL) AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE
Common Name English
RG-7601
Code English
VENETOCLAX [MI]
Common Name English
BENZAMIDE, 4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYL-1-CYCLOHEXEN-1-YL)METHYL)-1-PIPERAZINYL)-N-((3-NITRO-4-(((TETRAHYDRO-2H-PYRAN-4-YL)METHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)-
Common Name English
4-(4-((2-(4-CHLOROPHENYL)-4,4-DIMETHYLCYCLOHEX-1-EN-1-YL)METHYL)PIPERAZIN-1-YL)-N-((3-NITRO-4-((TETRAHYDRO-2H-PYRAN-4-YLMETHYL)AMINO)PHENYL)SULFONYL)-2-(1H-PYRROLO(2,3-B)PYRIDIN-5-YLOXY)BENZAMIDE
Systematic Name English
VENETOCLAX [WHO-DD]
Common Name English
GDC-0199
Code English
Classification Tree Code System Code
FDA ORPHAN DRUG 375612
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 780920
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
NDF-RT N0000192515
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 536116
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
EU-Orphan Drug EU/3/16/1617
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 664118
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 423814
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 506815
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 777520
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
NCI_THESAURUS C129824
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
WHO-ATC L01XX52
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 689119
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
FDA ORPHAN DRUG 600117
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
Code System Code Type Description
RXCUI
1747556
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
NCI_THESAURUS
C103147
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
EVMPD
SUB176260
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
PUBCHEM
49846579
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
WIKIPEDIA
Venetoclax
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
DRUG CENTRAL
5133
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
EPA CompTox
1257044-40-8
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
FDA UNII
N54AIC43PW
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
CAS
1257044-40-8
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
NDF-RT
N0000009176
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY Increased Cellular Death [PE]
NDF-RT
N0000185503
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY P-Glycoprotein Inhibitors [MoA]
ChEMBL
CHEMBL3137309
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
INN
9925
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
DRUG BANK
DB11581
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY
MERCK INDEX
M11932
Created by admin on Fri Jun 25 21:32:57 UTC 2021 , Edited by admin on Fri Jun 25 21:32:57 UTC 2021
PRIMARY